Immunitas Therapeutics

Immunitas Therapeutics

  • Founded: 2019
  • Location: Waltham, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2a
  • Therapy area: Multiple cancers
  • Drug types: ONC
  • Lead product: IMT-009
  • Product link:
  • Funding: $58M B Aug 2021; $39M Nov 2019

job board

Short description:

Single cell genomics-based drug discovery

Drug notes:

Also combo Clin0 multiple cancers; 2+ undisclosed programs RD undisclosed

Long description:

Immunitas Therapeutics is developing targeted therapeutics using knowledge of human immunology to treat various cancers. Using expertise in single-cell genomics with customized machine learning, Immunitas is elucidating immune cells populations that are key actors in immuno-oncology. Immunitas then complements this insight with in-house therapeutic discovery using antibody display and immunization. Their lead program, IMT-009, is a monoclonal antibody that is currently in clinical trials for solid tumor and hematological malignancies.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy